[Changes of protein expression in HepG2 cells with CDK2 RNA interference]

Jin Shang1, Zhenyu Wang, Junzao Li

  • 1Department of Dermatology, Frist Affiliated Hospital, Baotou Medical College, Baotou Public Security Bureau, China. shangjin.8299@yahoo.com.cn

Abstract

Insights

CDK2 siRNA significantly inhibited hepatocellular carcinoma HepG2 cell proliferation and CDK2 mRNA expression. Four novel proteins were identified as not expressed in treated cells, impacting cell biology.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Context:

  • Hepatocellular carcinoma (HCC) is a significant global health concern.
  • Cyclin-dependent kinase 2 (CDK2) plays a crucial role in cell cycle regulation and cancer progression.
  • Targeting CDK2 is a potential therapeutic strategy for HCC.

Purpose:

  • To investigate the effects of stable transfection of CDK2 siRNA on biological activities and nuclear proteins of human hepatocellular carcinoma HepG2 cells.
  • To assess the impact of CDK2 inhibition on cell proliferation, cell cycle, and protein expression profiles.

Summary:

  • Stable transfection of CDK2 siRNA in HepG2 cells significantly inhibited cell proliferation and reduced CDK2 mRNA expression.
  • Two-dimensional electrophoresis-mass spectrometry identified four proteins (ribosomal protein S12, β-actin, zinc finger 276, and chaperonin 10 related protein) that were not expressed in CDK2 siRNA-treated cells.
  • Western blotting confirmed the differential expression of these proteins.

Impact:

  • CDK2 siRNA demonstrates potential as a therapeutic agent for hepatocellular carcinoma by suppressing tumor growth.
  • Identification of novel proteins affected by CDK2 inhibition provides insights into HCC pathogenesis.
  • This study contributes to understanding the molecular mechanisms underlying HCC and informs the development of targeted therapies.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...